Refine by
Neurodegeneration Suppliers & Manufacturers
59 companies found
based inParis, FRANCE
Qynapse, through QyScore, brings groundbreaking peace of mind to the global fight against CNS disease. Qyscore is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI). Qyscore is a medical device software FDA-cleared ...
QyScore is a groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings. One scan at a time, QyScore has the potential to revolutionize the treatment of CNS disease and create the potential for earlier ...
based inSan Carlos, CALIFORNIA (USA)
Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and ...
Alkahest, with its partner Grifols, is developing lead clinical candidates, GRF6019 and GRF6021, as potential treatments for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. ...
based inWendelsheim, GERMANY
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound ...
Multiple System Atrophy (MSA) is a rare neurodegenerative disorder that belongs to the group of synucleinopathies and is also classified as an “atypical parkinsonism” disorder. Pathologically, MSA is characterized by abnormal deposits of ...
based inBethesda, MARYLAND (USA)
Gain Therapeutics is redefining drug discovery with its SEE-Txâ„¢ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for ...
Krabbe disease is a severe neurodegenerative disorder caused by mutations in GALC, the gene that encodes the galactosylceramidase (GALC) enzyme. These mutations cause GALC misfolding and dysfunction, which leads to the toxic buildup up fats in the ...
based inNes-Ziona, ISRAEL
Kadimastem is a bio-pharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. ...
Clinical grade human astrocytes (the nervous system supporting cells) for the treatment of ALS and other neurodegenerative diseases. Received approval by the Israeli Ministry of Health to commence our phase I/IIa clinical trial in ALS patients. 6 ...
based inSeongnam-si, SOUTH KOREA
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development ...
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening ...
based inMadison, WISCONSIN (USA)
Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include stem cell derived in vitro models for drug discovery and matrices for cell therapy and regenerative medicine. Stem Pharm was founded in 2015 with the ...
Stem Pharm’s advanced neural organoid models uniquely contain microglia and provide new opportunities to investigate CNS disease modeling, drug discovery, and toxicology applications. ...
based inWoburn, MASSACHUSETTS (USA)
As the scientific leader in the biological role of the microbiome gut-brain axis and its impact on neurological conditions, Axial Therapeutics is uniquely positioned to advance a fundamentally different therapeutic approach for the treatment of ...
based inMonterey, CALIFORNIA (USA)
Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a ...
INT41 has received Orphan Drug Designation from the FDA for Huntington’s disease. IND enabling studies for INT41 Gene Therapy for Huntington’s disease are in place following a preIND meeting with the FDA in in February 2022 in response ...
based inBozeman, MONTANA (USA)
Montana Molecular specializes in the development of fluorescent biosensors and reporters designed to facilitate drug discovery and research within living cells. With a focus on generating innovative solutions, the company provides tools that allow ...
based inMissoula, MONTANA (USA)
FYR Diagnostics is developing a powerful portfolio of biomarker detection technologies with a focus on nucleic acid amplification. Our mission is to commercialize and implement these novel technologies to enable the accelerated prediction, ...
based inSt. Louis, MISSOURI (USA)
C₂N’s Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around ...
The PrecivityAD® Blood Test Answers Calls from Patients, Advocates, and Healthcare Providers Who Want Earlier Answers. Summary of Test and Patient Selection. The PrecivityAD® test identifies whether a patient is likely to have the presence ...
based inDerio, SPAIN
Innoprot is a company specializing in the development and provision of high-quality cell lines and assays for use in research and drug discovery. They offer a wide array of G protein-coupled receptor (GPCR) cell lines, which are essential for ...
based inMagdeburg, GERMANY
HASOMED GmbH is an owner-managed family business. We grow from our own resources, independent of outside capital, 'with our feet on the ground'. The management acts in Christian responsibility. Committed employees are the most important capital of ...
based inLynnwood, WASHINGTON (USA)
Kurve Therapeutics drug delivery technology is designed to target the most difficult part of the treatment process - getting medication through the blood-brain barrier and into the brain. Kurve Therapeutics has 18 peer-reviewed publications of ...
based inDoylestown, PENNSYLVANIA (USA)
Neuropathix, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing a patented product platform of novel molecules from our proprietary socially responsible pain management therapeutics to treat patients with a ...
Neuropathix has focused its science on the research and development of a pipeline of next generation socially responsible pain management ...
based inParis, FRANCE
Iconeus, based in Paris, is renowned for pioneering the functional ultrasound technology specifically designed for imaging cerebrovascular activity. Their flagship product, the Iconeus One, integrates high-sensitivity, high-speed, and ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
The blood-brain barrier (BBB) penetrating technology is essential to develop drugs for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease, which have high unmet medical needs. MitoImmune has ...
based inNew York City, NEW YORK (USA)
Woolsey Pharmaceuticals is focused on the treatment of rare, neurodegenerative diseases. Many neurodegenerative diseases – including Alzheimer’s, vascular dementia, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as motor neuron diseases. Motor neurons reach from the brain to ...
based inJerusalem, ISRAEL
BrainQ Technologies developing breakthrough precision neurology therapies using Brain Computer Interface technology. BrainQ’s goal is to develop therapies that target damaged neuronal networks and facilitate neurorecovery. We are developing a ...
BrainQ’s device uses non-invasive, frequency-tuned extremely low frequency and low intensity electromagnetic fields (ELF-EMF) with aim of promoting neurological recovery in the central nervous system (CNS). The artificial intelligence ...